A 12-week Study to Compare the Efficacy and Safety of Albuterol Spiromax® Versus a Placebo in People 12 Years and Older With Persistent Asthma
Public ClinicalTrials.gov record NCT01424813. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A 12-week Comparison of the Efficacy and Safety of Albuterol Spiromax® Versus Placebo in Subjects 12 Years and Older With Persistent Asthma
Study identification
- NCT ID
- NCT01424813
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Industry
- Enrollment
- 158 participants
Conditions and interventions
Conditions
Interventions
- Placebo MDPI Drug
- Albuterol MDPI Drug
Drug
Eligibility (public fields only)
- Age range
- 12 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 30, 2012
- Primary completion
- Sep 30, 2013
- Completion
- Oct 31, 2013
- Last update posted
- Jun 25, 2015
2012 – 2013
United States locations
- U.S. sites
- 38
- U.S. states
- 19
- U.S. cities
- 33
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Teva Investigational Site 10077 | Birmingham | Alabama | — | — |
| Teva Investigational Site 10079 | Phoenix | Arizona | — | — |
| Teva Investigational Site 10569 | Costa Mesa | California | — | — |
| Teva Investigational Site 10053 | Fountain Valley | California | — | — |
| Teva Investigational Site 10065 | Huntington Beach | California | — | — |
| Teva Investigational Site 10572 | Huntington Beach | California | — | — |
| Teva Investigational Site 10075 | Los Angeles | California | — | — |
| Teva Investigational Site 10061 | Roseville | California | — | — |
| Teva Investigational Site 10066 | San Diego | California | — | — |
| Teva Investigational Site 10068 | Denver | Colorado | — | — |
| Teva Investigational Site 10069 | Denver | Colorado | — | — |
| Teva Investigational Site 10058 | Miami | Florida | — | — |
| Teva Investigational Site 10060 | Miami | Florida | — | — |
| Teva Investigational Site 10064 | Ormond Beach | Florida | — | — |
| Teva Investigational Site 10071 | Savannah | Georgia | — | — |
| Teva Investigational Site 10073 | Wichita | Kansas | — | — |
| Teva Investigational Site 10070 | Owensboro | Kentucky | — | — |
| Teva Investigational Site 10063 | Bethesda | Maryland | — | — |
| Teva Investigational Site 10571 | Gaithersburg | Maryland | — | — |
| Teva Investigational Site 10067 | Wheaton | Maryland | — | — |
| Teva Investigational Site 10072 | St Louis | Missouri | — | — |
| Teva Investigational Site 10050 | Missoula | Montana | — | — |
| Teva Investigational Site 10057 | Raleigh | North Carolina | — | — |
| Teva Investigational Site 10051 | Cincinnati | Ohio | — | — |
| Teva Investigational Site 10078 | Sylvania | Ohio | — | — |
| Teva Investigational Site 10054 | Oklahoma City | Oklahoma | — | — |
| Teva Investigational Site 10568 | Oklahoma City | Oklahoma | — | — |
| Teva Investigational Site 10055 | Tulsa | Oklahoma | — | — |
| Teva Investigational Site 10056 | Medford | Oregon | — | — |
| Teva Investigational Site 10076 | Medford | Oregon | — | — |
| Teva Investigational Site 10684 | Charleston | South Carolina | — | — |
| Teva Investigational Site 10570 | Spartanburg | South Carolina | — | — |
| Teva Investigational Site 10049 | Live Oak | Texas | — | — |
| Teva Investigational Site 10052 | San Antonio | Texas | — | — |
| Teva Investigational Site 10685 | Waco | Texas | — | — |
| Teva Investigational Site 10059 | Fairfax | Virginia | — | — |
| Teva Investigational Site 10074 | Puyallup | Washington | — | — |
| Teva Investigational Site 10062 | Tacoma | Washington | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01424813, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 25, 2015 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01424813 live on ClinicalTrials.gov.